基本信息
张翾  男  硕导  中国科学院上海药物研究所
电子邮件: zhangxuan@simm.ac.cn
通信地址: 上海市松涛路647弄2幢2-226
邮政编码: 201203

招生信息

   
招生专业
100701-药物化学
招生方向
蛋白降级剂的设计与生物学研究

教育背景

2009-09--2014-05   华东师范大学   博士学位
2001-09--2005-06   上海师范大学   学士学位

工作经历

   
工作简历
2019-07~2020-12,美国佛罗里达大学, 科研助理教授
2018-06~2019-07,美国佛罗里达大学, 博士后
2014-12~2018-05,美国阿肯色大学医学部, 博士后
2014-08~2014-11,华东师范大学, 科研助理
2005-07~2009-09,中国科学院上海药物研究所, 研究助理

专利与奖励

   
专利成果
( 1 ) Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof, 发明, 2016, 第 3 作者, 专利号: PCT/US2017/028875

出版信息

   
发表论文
(1) A Concise Synthesis of (S)-δ-CEHC, a Metabolite of Vitamin E, ACS Omega, 2021, 通讯作者
(2) Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells, Nat. Commun., 2021, 其他(合作组作者)
(3) Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs, Chem. Commun., 2020, 通讯作者
(4) Using proteolysis targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity, Nat. Commun., 2020, 第 2 作者
(5) Discovery of IAP-Recruiting BCL-XL PROTACs as Potent Degraders across Multiple Cancer Cell Lines, Eur. J. Med. Chem., 2020, 第 1 作者
(6) Discovery of PROTAC BCL-XL Degraders as Potent Anticancer Agents with Low On-target Platelet Toxicity, Eur. J. Med. Chem., 2020, 第 1 作者
(7) Targeting anti-apoptotic BCL-2 family proteins for cancer treatment, Future Med. Chem., 2020, 第 1 作者
(8) Recent advances in small molecular modulators targeting histone deacetylase 6, Future Drug Discov., 2020, 通讯作者
(9) PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors, Explor. Targeted Antitumor Ther., 2020, 第 2 作者
(10) Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies, J. Hematol. Oncol., 2020, 第 5 作者
(11) DT2216 – a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T-cell lymphomas, J. Hematol. Oncol., 2020, 第 5 作者
(12) PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics, Oncogene, 2020, 第 3 作者
(13) Assays and Technologies for Developing Proteolysis Targeting Chimera Degraders, Future Med. Chem., 2020, 第 2 作者
(14) Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity, Aging Cell, 2020, 第 5 作者
(15) Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorine‐Substituted δ‐Tocotrienol Derivative, ChemMedChem, 2020, 第 5 作者
(16) Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production, Bioorg. Med. Chem., 2020, 第 6 作者
(17) Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL. Chem. Commun, Chem. Commun., 2019, 第 1 作者
(18) A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity, Nat. Med., 2019, 第 2 作者

科研活动

   
参与会议
(1)Discovery of BCL-XL degraders as potent and platelet-sparing anticancer agents   2019-08-26
(2)Induced Degradation of Bcl-xL: A PROTAC Approach to Target the Achilles’ Heel of Senescent Cells   2017-09-26